DC_AC50 是一种 Atox和CCS 的双抑制剂，是一种抑制细胞内铜伴侣作为减少/预防获得性化疗耐药性的手段。它与 Atox1 和 CCS 结合并减少癌细胞增殖和肿瘤生长。

DC_AC50 is a dual inhibitor of Atox1 and CCS (copper chaperones). Inhibiting intracellular copper chaperones as a means of reducing/preventing acquired chemotherapy resistance.DC_AC50 binding to Atox1 and CCS and reducing cancer cell proliferation and tumour growth.

DC_AC50 synergised with carboplatin in combination treatment of human and canine OSA cells to reduce cancer cell viability.?DC_AC50-treated cells were significantly less mitotically active, as demonstrated by decreased expression of phospho-histone H3 and cell cycle analysis.?DC_AC50 also potentiated carboplatin-induced apoptosis in OSA cells and decreased clonogenic survival.?Finally, DC_AC50 reduced the migratory ability of OSA cells.?These results justify further investigation into inhibiting intracellular copper chaperones as a means of reducing/preventing acquired chemotherapy resistance.

497061-48-0

C17H12BrF2N3OS

424.26

DMSO:10 mM
Powder: -20°C for 3 years
In solvent: -80°C for 2 years